Cancer Medicine (Mar 2020)

Race, tumor location, and disease progression among low‐risk prostate cancer patients

  • Justin G. Mygatt,
  • Jennifer Cullen,
  • Samantha A. Streicher,
  • Huai‐Ching Kuo,
  • Yongmei Chen,
  • Denise Young,
  • William Gesztes,
  • Grant Williams,
  • Galen Conti,
  • Christopher Porter,
  • Sean P. Stroup,
  • Kevin R. Rice,
  • Inger L. Rosner,
  • Allen Burke,
  • Isabell Sesterhenn

DOI
https://doi.org/10.1002/cam4.2864
Journal volume & issue
Vol. 9, no. 6
pp. 2235 – 2242

Abstract

Read online

Abstract Background The relationship between race, prostate tumor location, and BCR‐free survival is inconclusive. This study examined the independent and joint roles of patient race and tumor location on biochemical recurrence‐free (BCR) survival. Methods A retrospective cohort study was conducted among men with newly diagnosed, biopsy‐confirmed, NCCN‐defined low risk CaP who underwent radical prostatectomy (RP) at the Walter Reed National Military Medical Center from 1996 to 2008. BCR‐free survival was modeled using Kaplan‐Meier estimation curves and multivariable Cox proportional hazards (PH) analyses. Results There were 539 eligible patients with low‐risk CaP (25% African American, AA; 75% Caucasian American, CA). Median age at CaP diagnosis and post‐RP follow‐up time was 59.2 and 8.1 years, respectively. Kaplan‐Meier analyses showed no significant association between race (P = .52) or predominant tumor location (P = .98) on BCR‐free survival. In Cox PH multivariable analysis, neither race (HR = 1.18; 95% CI = 0.68‐2.02; P = .56) nor predominant tumor location (HR = 1.13; 95% CI = 0.59‐2.15; P = .71) was an independent predictor of BCR‐free survival. Conclusions Neither race nor predominant tumor location was associated with adverse oncologic outcome.

Keywords